Inhibrx Prevails in Trade Secret Case, Reaffirming Its Commitment to Integrity and Innovation

Core Viewpoint - Inhibrx Biosciences, Inc. achieved a significant legal victory in a trade secrets case against I-Mab Biopharma, with the jury rejecting all allegations of misappropriation, thereby affirming the company's ethical standards and innovative research practices [1][2][3]. Legal Case Summary - I-Mab initiated the lawsuit on March 1, 2022, claiming that Inhibrx and its Chief Scientific Officer improperly accessed proprietary information during a prior arbitration [2]. - The jury found no basis for I-Mab's claims, validating Inhibrx's independent development processes and ethical conduct [2][3]. Company Values and Commitment - Inhibrx was founded on principles of integrity and scientific excellence, focusing on advancing novel therapeutics for patients [3][4]. - The company emphasized its commitment to independent development and protecting intellectual property throughout the trial [3]. Future Focus - Following the verdict, Inhibrx aims to concentrate on delivering life-changing therapies to patients globally, expressing gratitude for the support received during the legal process [5]. - The company continues to develop a broad pipeline of novel biologic therapeutic candidates in oncology, utilizing advanced protein engineering methods [6].